1
Study to Evaluate the PK of IV and PO Omadacycline in Children and Adolescents With Suspected or Confirmed Bacterial Infections
Condition(s):Bacterial InfectionsLast Updated:May 19, 2022Recruiting
NUZYRA: 15 Clinical Trials, Page 1 of 2
Hide Studies Not Open or Pending
2
Omadacycline Tissue Penetration in Diabetic Patients With Wound Infections and Healthy Volunteers Via In Vivo Microdialysis
Condition(s):Diabetes; Wound Infection; Healthy VolunteersLast Updated:August 25, 2021Completed
3
Oral Omadacycline vs. Placebo in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex (MABc)
Condition(s):Mycobacterium Infections, Nontuberculous; Mycobacterium Abscessus Infection; Nontuberculous Mycobacterial Lung Disease; Nontuberculous Mycobacterial Pulmonary InfectionLast Updated:April 19, 2022Recruiting
4
Omadacycline vs. Moxifloxacin for the Treatment of Community-Acquired Bacterial Pneumonia
Condition(s):Community-acquired Pneumonia; Bacterial PneumoniaLast Updated:May 20, 2022Recruiting
5
Pharmacokinetics of Omadacycline in Cystic Fibrosis
Condition(s):Cystic FibrosisLast Updated:September 24, 2021Recruiting
6
Study to Evaluate the PK of PO Omadacycline in Adults With Community-Acquired Bacterial Pneumonia
Condition(s):Community-acquired PneumoniaLast Updated:November 3, 2021Completed
7
IV or IV/PO Omadacycline vs. IV/PO Levofloxacin for the Treatment of Acute Pyelonephritis
Condition(s):Acute PyelonephritisLast Updated:July 7, 2020Completed
8
Study the Safety and Efficacy of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI)
Condition(s):Skin Diseases, InfectiousLast Updated:March 12, 2021Terminated
9
Oral Omadacycline vs. Oral Linezolid for the Treatment of ABSSSI
Condition(s):Bacterial Infections; Skin Structures and Soft Tissue InfectionsLast Updated:November 30, 2018Completed
10
Study the Efficacy and Safety of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI)
Condition(s):Infectious Skin Disease; Bacterial Skin DiseaseLast Updated:October 12, 2020Completed